secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0001171843-24-004422
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst Q2 ORLADEYO revenue up 34% to $108.3M; raises FY guidance to $420-435M
-------------------------------------------------------------------------------

- Q2 total revenue $109.3M (+32.5% YoY); GAAP operating profit $8.8M vs loss $20.7M in Q2 2023.
- Net loss narrowed to $12.7M ($0.06/share) from $75.3M ($0.40/share); non-GAAP operating profit $21.9M.
- ORLADEYO FY2024 revenue guidance raised to $420-435M from $390-400M, citing strong demand and payer improvements.
- Discontinuing oral Factor D inhibitor BCX10013 due to insufficient activity; advancing BCX17725 for Netherton syndrome to clinic by end-2024.
- Cash $338.1M vs $415.7M a year ago; operating cash use was only $0.2M in Q2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184324004422/0001171843-24-004422-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184324004422/f8k_080524.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-004422

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer